8-K current report · filed Nov 5, 2026

Astrana Health, Inc. (ASTH) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2ASTH overview

Short answer

Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.

Astrana Health, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details

Item 7.01 · Regulation FD Disclosure

  • Conference call and webcast scheduled for November 5, 2026 at 2:30 p.m. Pacific Time
  • Discussion covers financial results for the three and nine months ended September 30, 2026
  • Earnings presentation available through Astrana Health’s investor relations website and Exhibit 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $1,023.6M, up 7%, with adjusted EBITDA $77.2M, up 13%, signaling operating leverage
  • Net income attributable to Astrana $13.0M versus $0.4M, while adjusted EPS reached $0.71 versus $0.68
  • Nine-month revenue $2,961.2M, up 33%, and adjusted EBITDA $212.4M, up 39%, strengthening full-year growth visibility
  • Nine-month operating cash flow $117.1M and free cash flow $105.4M, supporting liquidity despite $115.9M of debt repayments
  • 2026 guidance narrowed to revenue $3.9B-$4.0B, adjusted EBITDA $261M-$274M, and free cash flow $107.5M-$130M

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $1,023.6M, up 7%, with capitation reaching $936.7M and signaling continued value-based care expansion
  • Adjusted EBITDA $77.2M, up 13%, while margin improved to 8% from 7%, indicating operating leverage
  • Net income attributable to Astrana $13.0M versus $0.4M, reflecting a sharp year-over-year earnings improvement
  • FY2026 guidance narrowed to revenue $3,900-$4,000M and adjusted EBITDA $261-$274M, implying 24.1% and 30.2% midpoint growth
  • Full-risk exposure expanding, with 82% of capitation revenue expected under full-risk arrangements and 43% of Care Partners members by year-end

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Astrana Health, Inc. 8-K filings

Get the next ASTH 8-K as it lands

Follow ASTH for push alerts, or ask the research agent what this filing means.